



JOSH SHIN

Partner-Shanghai

+86 21 2208 1109

jshin@fangdalaw.com

PRACTICE AREA

MR. JOSH SHIN SPECIALIZES IN CORPORATE AND COMMERCIAL LAW MATTERS, WITH EXTENSIVE EXPERIENCES IN VARIOUS INDUSTRY SECTORS SUCH AS PHARMA, LIFE SCIENCES, PRIVATE EDUCATION AND GENERAL INDUSTRIES SECTORS.

Education

- University College London (UCL), Faculty of Law, LL.M
- Fudan University, School of Law, LL.B

Professional Qualification

- Admitted to practice in the PRC

Mr. Shin maintains a balanced practice between transactional and regulatory advisory matters. Leading the life sciences practice within the firm's corporate group, Josh is well-versed in advising clients on a wide range of legal matters. He is considered as one of the most active and influential Chinese lawyers in various types of transactions in relevant industries sectors, such as licensing and collaboration and M&A deals. In these transactional works, his "good business sense" and keen understanding of client needs have earned him praise from those he has worked with. Additionally, Mr. Shin has a proven track record in advising clients on regulatory-related issues covering a variety of cutting-edge legal issues. Josh's clientele commended him that "Finding someone who always has sight of the bigger picture while diving into the smallest details to ensure the quality of work product is not easy. Josh has distinguished himself for his professionalism, enthusiasm to the career and sensitivity of industry."

REPRESENTATIVE MATTERS AND CASES

M&A/Corporate Transactions:

- Representing Excalipoint (a Cayman Newco) in securing US\$41 million Series A financing (co-led by Hongshan Capital, YuanBio Capital and Apricot Capital), and obtaining the global exclusive license for two T-cell engager pipelines from Lepu Biopharma covering development, production and commercialization rights.
- Representing AstraZeneca Global Ventures in its equity investments in several China headquartered biotech companies, including FuseBio and SyneronBio.
- Representing AnHeart Therapeutics on its full acquisition by Nuvation Bio, a US biopharmaceutical company listed on NYSE (NYSE: NUVB), in an all-stock transaction.
- Representing AnHeart Therapeutics in its cross-border restructuring and Series A+/A-2/B/C equity financing.
- Representing E-Shang Redwood in its series acquisitions/disposals of 30+ logistic assets in China.
- Representing AstraZeneca in its investment of new manufacturing facilities in Qingdao, Taizhou and Wuxi for a total value of RMB10 billion.
- Representing Redwood China Logistics Fund and other sellers in the sale of top tier logistics assets in PRC mainland to the entity established by ESR and Manulife Financial Group.
- Representing multiple life sciences start-ups, such as Cascade, EddingPharm and MitrAssist, in their various

rounds of equity financing.

- Representing Eddingpharm on its acquisition from Eli Lilly of the rights for two legacy antibiotic medicines in China: Ceclor and Vancocin, as well as a manufacturing facility in Suzhou.
- Representing Bayer Healthcare China in selling its TCM products and manufacturing plant to a leading Chinese pharmaceutical company.
- Representing Education Index Management (the owner of Dulwich College International) in its various rounds of private equity financing and restructuring of its China business.
- Representing Everbright Holdings in its investment in Shenzhen Lifetech (01302.HK), the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases.
- Representing Ping'An, ARA, LOGOS, and SunJade Capital in its series acquisitions of logistic assets in China.
- Representing Bayer HealthCare China in reorganization its corporate structure for integration with the onshore part of Merck OTC Business, following Bayer's global acquisition of Merck OTC department.
- Representing Bayer AG in its acquisition of 100% interest in Dihon Pharmaceutical Group, a leading OTC and traditional Chinese medicine company in China.
- Representing Wuxi AppTec in forming a joint venture with Mayo Clinics regarding advanced medical examination technologies.
- Representing World Strides, the largest educational travel company in the world, in acquiring summer camping business in China.
- Representing Parkway Health, a leading healthcare services provider in Asia in its investment into several private hospitals and clinics in various provinces in China.

Product License/Collaboration:

- Representing Kyowa Kirin in its Asia-Pacific business restructuring, which involved transferring entire interest of Kyowa Kirin China to WinHealth Pharma through a series of transactions, while granting WinHealth: Commercialization and production rights in China for five commercial-stage originator brand pharmaceuticals, and China commercialization rights for two global products.
- Represented AstraZeneca in multiple combination study projects with certain biopharma companies including Ascentage Pharma, Wuxi BioCity, Shanghai JMT and Genhouse.
- Represented Duality Bio (9606.HK) in granting commercialization rights to 3SBio's subsidiary Shenyang 3SBio for multiple indications of the DB-1303 product (a HER2 antibody-drug conjugate) in mainland China, Hong Kong, and Macau.
- Represented TJ Bio to enter into a strategic collaboration with Sanofi for developing, manufacturing and commercializing the globally innovative asset CD73 monoclonal antibody (Uliledlimab) in Greater China.
- Represented Henlius (2696.HK) in licensing E-602 from Palleon Pharmaceuticals for the Greater China region and in reaching a global collaboration on combo therapy with Palleon Pharmaceuticals.
- Represented CSPC's wholly-owned subsidiary Shanghai JMT-BIO to enter into an exclusive license agreement with Jiangsu Alphamab for developing and commercializing JSKN003 (a biparatopic HER2-targeting antibody-drug conjugate/ADC) in Mainland China, with upfront payment plus near-term development milestones amounting to approx. US\$100 million.
- Representing Kanghwa in granting HilleVax the exclusive rights to develop, manufacture and commercialize Kanghwa's hexavalent virus-like particle (VLP) vaccine candidate for norovirus in the ex-Greater China territory.
- Represented Hengrui Pharmaceuticals in its out-licensing partnership with Aiolos Bio with respect to Hengrui's innovative anti-TSLP monoclonal antibody (SHR-1905) in ex-Greater China territory.
- Represented CStone Pharmaceuticals in out-licensing of exclusive development, registration, manufacturing and commercialization right related to anti-PD-1 monoclonal antibody (nofazinlimab) in mainland China to 3SBio Inc.
- Representing multiple MNCs in exclusive promotion and/or CSO arrangements with respect to their core

products with partners in China market.

- Representing AstraZeneca in reaching a co-promotion arrangement with Daiichi Sankyo of DS8201 in China market following a global license of DS8201.
- Representing CStone Pharmaceuticals in granting the exclusive rights to Hengrui Pharmaceuticals for research, development, registration, manufacturing, and commercialization of anti-CTLA-4mAb CS1002 in the Greater China region.
- Representing medical devices companies including Baxter and Cordis, in connection with its contract design, contract R&D and contract manufacturing transaction in China market.
- Representing OnCusp Therapeutics in obtaining global (ex-China) exclusive license to an ADC drug candidate from Multitude Therapeutics.
- Representing Anheart Therapeutics, in granting exclusive commercialization right in PRC market with respect to Anheart's lead drug candidate talectrectinib, a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and NTRK to Innovent, in China Market and to Nippon Kayaku, a listed company in Japan, in Japan market respectively.
- Representing AstraZeneca in granting to BioKangtai the exclusive license in China with respect to the AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University.
- Representing AstraZeneca in obtaining the exclusive promotion rights Luye Pharmaceuticals with respect to Xue Zhi Kang Capsule, a first-line blood lipid management drug. This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.
- Representing AstraZeneca in its granting of exclusive commercialization rights to Plendil in China market to China Medical System for an upfront fee of USD310 million and ongoing economic sharing.
- Representing AstraZeneca in its granting of exclusive commercialization rights to certain GLP-1 diabetes drugs in China market to 3Sbio for an upfront fee of USD100 million and ongoing economic sharing.

General Corporate/Regulatory Works:

- Representing Johnson Matthey, Covestro AG, E-Shang Redwood, Education Index Management, Nord Anglia, Celanese and a number of other companies, in regulatory issues arising from daily business.
- Representing life sciences companies including AstraZeneca, BMS, Bria, AnHeart Therapeutics, Pfizer, Organon, SmithKline, Vantive, Novartis AG, Boehringer Ingelheim, Roche Pharmaceuticals, C-Stone Pharmaceuticals, Zai Lab, Biogen, Tonghua Dongbao, Duality Bio and Henlius, in regulatory and compliance issues arising from daily business, including research and development projects, clinical trials, responding to investigation and enforcement actions from drug regulating authorities, market authorization, product distribution, PAP/PSP, PBM, product promotion, and NGO/PAG interactions.
- Advising Dulwich College International China schools, Dehong Chinese International School, Shanghai Concord Bilingual School and Nord Anglia schools on various legal issues in daily operation, including new school opening, campus construction/expansion, regulatory compliance, related party transaction, procurement, data protection, school management, debt financing, etc.

Presentations/Speeches

- As a leading industry figure, Josh has been routinely invited to give speeches or participate in panel discussions at professional conferences and forums in different countries, sharing his insights on life sciences industries, BD and M&A transactions, and compliance issues.

Publications/Articles

- Lead Author “Pharma Legal Handbook - PRC” published by Pharma Boardroom (edition 2019 and 2021).
- Co-author, “China life sciences: Transaction insights and notable industry trends”, Legal 500 (Feb 2024).
- Co-author, “Life Sciences Yearbook 2024: China life sciences Q&A “, Legal 500 (Feb 2024).

Honors and Awards

- Recommended as leading lawyer for healthcare by Chambers and Partners – Asia Pacific 2019 through 2021 and by Chambers and Partners - Greater China 2022 through 2025.
- Recommended as leading individual for “healthcare and life-science” by Legal 500 –Asia Pacific 2020 through 2024.
- Recommended as distinguished practitioner in Healthcare legal services by Asia Law 2022 and 2024.
- Pharmaceutical, Medical and Biotech M&A Legal Advisor of the Year 2019, by Merger Market.
- Awarded jointly by China Health Consulting and CITIC Securities as “Top 5 Practitioners in Healthcare Sector” in 2023

Professional Affiliations

- Josh has been dedicated to public welfare and the professional growth of young professionals for many years, and is an active contributor and former council member of NGLegal, a youth legal development program.
 - Currently serves as Deputy Director of the Legal & Compliance Committee, Shanghai Biopharmaceutical Association
-